ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2010
Evaluation status and prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in pediatric high grade gliomas.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Impact of tumor location and pathological discordance on survival of children with midline high-grade gliomas treated on Children's Cancer Group high-grade glioma study CCG-945.Journal of neuro-oncology · 2015Trial
- Precision diagnosis and therapy for pediatric central nervous system tumors: consensus from the Brazilian Society of Pediatric Oncology (SOBOPE).Lancet regional health. Americas · 2026Review
- Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas.Frontiers in oncology · 2024Review
- Novel Pharmacological Treatment Options in Pediatric Glioblastoma-A Systematic Review.Cancers · 2022Review
- Review
- WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial.Neuro-oncology · 2020Article
- MGMT testing allows for personalised therapy in the temozolomide era.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Pediatric glioblastoma: a single institution experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016Article
- Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).International journal of oncology · 2015Review
- Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment.BioMed research international · 2015Review
- Progression of O⁶-methylguanine-DNA methyltransferase and temozolomide resistance in cancer research.Molecular biology reports · 2014Review
- Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.Nature reviews. Cancer · 2014Review
- Are pediatric brain tumors on the rise in the USA? Significant incidence and survival findings from the SEER database analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2014Article
- MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2011Article
- MGMT promoter methylation in pediatric high-grade gliomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2011Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn this study, we investigated the prognostic and predictive value of MGMT promoter methylation and protein expression in 30 pediatric high grade gliomas (pHGG).
methodsMGMT promoter methylation was assayed by methylation-specific polymerase chain reaction (MSP), whereas MGMT protein expression was evaluated by immunohistochemistry (IHC).
resultsMGMT promoter methylation was observed in 7/24 (30%) cases, whereas MGMT protein overexpression was found in 19/28 (68%) cases with similar distribution in grade III and grade IV gliomas. Median survival of methylated and unmethylated patients was 16 and 8 months, respectively. Moreover, overall survival and progression-free survival showed a trend toward reduction in patients with unmethylation (p = 0.9 and p = 0.7, respectively). For MGMT protein expression, the median survival was 8.5 and 17 months for patients with MGMT overexpression or low expression, respectively. Although these two groups did not show statistically significant differences in terms of overall survival or progression-free survival (p = 0.8 and p = 0.7, respectively), there was a significant correlation between MGMT protein expression and MGMT promoter methylation status (p = 0.01).
conclusionsOur findings indicate that, in pHGG, (a) MGMT promoter methylation is less frequent than in adult malignant gliomas, (b) there is a high correlation between MGMT MSP and MGMT IHC, and (c) as in adults, MGMT status is associated with prognosis, although this observation has to be statistically validated on larger series of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.